Bernd Liedert

961 total citations
18 papers, 777 citations indexed

About

Bernd Liedert is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Bernd Liedert has authored 18 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Bernd Liedert's work include Biosimilars and Bioanalytical Methods (4 papers), DNA Repair Mechanisms (3 papers) and Cancer Treatment and Pharmacology (3 papers). Bernd Liedert is often cited by papers focused on Biosimilars and Bioanalytical Methods (4 papers), DNA Repair Mechanisms (3 papers) and Cancer Treatment and Pharmacology (3 papers). Bernd Liedert collaborates with scholars based in Germany, Switzerland and Italy. Bernd Liedert's co-authors include Jürgen Thomale, Verena Materna, Hermann Lage, Jüergen Thomale, Zaza Katsarava, Dirk Schadendorf, Volker Limmroth, Min‐Suk Yoon, Anna Dzagnidze and Holger Kaube and has published in prestigious journals such as Nucleic Acids Research, Journal of Neuroscience and Blood.

In The Last Decade

Bernd Liedert

18 papers receiving 757 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bernd Liedert Germany 14 359 309 155 131 72 18 777
Jan Scicinski United States 16 318 0.9× 425 1.4× 145 0.9× 39 0.3× 120 1.7× 48 896
Sudhir B. Kondapaka United States 17 495 1.4× 909 2.9× 86 0.6× 128 1.0× 248 3.4× 21 1.5k
Donghai Dai United States 21 307 0.9× 443 1.4× 263 1.7× 71 0.5× 204 2.8× 50 1.2k
Xiaoting Hong China 14 207 0.6× 672 2.2× 114 0.7× 163 1.2× 150 2.1× 28 988
William Fieles United States 10 401 1.1× 612 2.0× 149 1.0× 50 0.4× 26 0.4× 13 1.1k
Rosana Meyer United States 23 308 0.9× 1.1k 3.5× 187 1.2× 62 0.5× 220 3.1× 37 1.4k
Raphaël Pineau France 19 150 0.4× 585 1.9× 142 0.9× 41 0.3× 195 2.7× 38 1.2k
Stacey Tannheimer United States 15 183 0.5× 447 1.4× 140 0.9× 130 1.0× 135 1.9× 32 888
Susana García‐Recio Spain 15 522 1.5× 480 1.6× 265 1.7× 46 0.4× 268 3.7× 26 1.2k
Sharmila Patel United States 13 216 0.6× 609 2.0× 165 1.1× 46 0.4× 135 1.9× 23 1.3k

Countries citing papers authored by Bernd Liedert

Since Specialization
Citations

This map shows the geographic impact of Bernd Liedert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Liedert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Liedert more than expected).

Fields of papers citing papers by Bernd Liedert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernd Liedert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Liedert. The network helps show where Bernd Liedert may publish in the future.

Co-authorship network of co-authors of Bernd Liedert

This figure shows the co-authorship network connecting the top 25 collaborators of Bernd Liedert. A scholar is included among the top collaborators of Bernd Liedert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernd Liedert. Bernd Liedert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Hemmer, Bernhard, Heinz Wiendl, Karsten Roth, et al.. (2023). Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology. 80(3). 298–298. 21 indexed citations
2.
3.
Kim, Edward S., et al.. (2021). Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC. JTO Clinical and Research Reports. 3(1). 100248–100248. 5 indexed citations
4.
Hanauer, Stephen B., et al.. (2021). Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. ˜The œLancet. Gastroenterology & hepatology. 6(10). 816–825. 30 indexed citations
5.
6.
Laurent, Julien, Cédric Touvrey, Silke Gillessen, et al.. (2013). T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. Journal of Translational Medicine. 11(1). 5–5. 26 indexed citations
7.
Gillessen, Silke, Ulrike Gnad-Vogt, Elisa Gallerani, et al.. (2012). A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. European Journal of Cancer. 49(1). 35–44. 45 indexed citations
8.
9.
Yoon, Min‐Suk, Zaza Katsarava, Mark Obermann, et al.. (2009). Erythropoietin overrides the triggering effect of DNA platination products in a mouse model of Cisplatin-induced neuropathy. BMC Neuroscience. 10(1). 77–77. 23 indexed citations
10.
Waibler, Zoe, Christel Kamp, Jan Müller‐Berghaus, et al.. (2008). Toward experimental assessment of receptor occupancy: TGN1412 revisited. Journal of Allergy and Clinical Immunology. 122(5). 890–892. 31 indexed citations
11.
Liedert, Bernd, S. Bassus, Cindy Schneider, Ulrich Kalinke, & Johannes Löwer. (2007). Safety of Phase I clinical trials with monoclonal antibodies in Germany – the regulatory requirements viewed in the aftermath of the TGN1412 disaster. International Journal of Clinical Pharmacology and Therapeutics. 45(1). 1–10. 8 indexed citations
12.
Dzagnidze, Anna, Zaza Katsarava, Julia Makhalova, et al.. (2007). Repair Capacity for Platinum-DNA Adducts Determines the Severity of Cisplatin-Induced Peripheral Neuropathy. Journal of Neuroscience. 27(35). 9451–9457. 131 indexed citations
13.
Thomas, Jan Peter, et al.. (2006). High Accumulation of Platinum-DNA Adducts in Strial Marginal Cells of the Cochlea Is an Early Event in Cisplatin but Not Carboplatin Ototoxicity. Molecular Pharmacology. 70(1). 23–29. 76 indexed citations
14.
Liedert, Bernd. (2006). Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Research. 34(6). e47–e47. 90 indexed citations
15.
Materna, Verena, Bernd Liedert, Jürgen Thomale, & Hermann Lage. (2005). Protection of platinum–DNA adduct formation and reversal of cisplatin resistance by anti‐MRP2 hammerhead ribozymes in human cancer cells. International Journal of Cancer. 115(3). 393–402. 69 indexed citations
16.
Liedert, Bernd, Verena Materna, Dirk Schadendorf, Jürgen Thomale, & Hermann Lage. (2003). Overexpression of cMOAT (MRP2/ABCC2) Is Associated with Decreased Formation of Platinum-DNA Adducts and Decreased G2-Arrest in Melanoma Cells Resistant to Cisplatin. Journal of Investigative Dermatology. 121(1). 172–176. 102 indexed citations
17.
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Scicinski Breakdown of academic impact, for papers by Sudhir B. Kondapaka Breakdown of academic impact, for papers by Donghai Dai Breakdown of academic impact, for papers by Xiaoting Hong Breakdown of academic impact, for papers by William Fieles Breakdown of academic impact, for papers by Rosana Meyer Breakdown of academic impact, for papers by Raphaël Pineau Breakdown of academic impact, for papers by Stacey Tannheimer Breakdown of academic impact, for papers by Susana García‐Recio Breakdown of academic impact, for papers by Sharmila Patel
Rankless by CCL
2026